24 October 2019 | News
Osteopore gets recognition for its innovative healthcare product at TCT award
image credit- osteopore.com
Osteopore, an Australian medical device company that designs and manufactures regenerative implants made via 3D printing, has been highly commended at the prestigious TCT Awards, at the National Conference Centre in Birmingham, where industry leaders celebrate innovators, technologies, and collaborators behind the best examples of Additive Manufacturing (AM), 3D Printing, and Design and Engineering around the world.
This year, Osteopore was highly commended in the TCT Healthcare Application section for its unique 3D regenerative implant which has significantly improved the Quality-of-Life of patients suffering from traumatic bone loss. Until 2018, Osteopore has helped more than 20,000 patients. With 15 competitive award categories which includes Aerospace, Automotive and Creative Application, Healthcare Application is considered one of the more rewarding industries to be involved with, according to the awards organiser.
TCT Awards also pointed out that 3D technology in this industry "couldn't be more fitting" and the capability to produce bespoke parts from scanned information is perhaps "more suited to this industry than any other".
Osteopore's acknowledgement at the TCT Awards is just the latest in a string of accreditations and accomplishments it has received over the past few months.
Last month, the global bone regeneration technology provider once again won top prizes at the prestigious Brands For Good awards in Singapore. Clinching the Champion for Patent Improving Lives 2019 and Winner for Community 2019 awards, Osteopore's wins mark the second consecutive year of wins at the event which shows recognition to businesses that not only make a difference to the community or the world but are also committed to creating a positive impact on people.
In the same month, Osteopore also debuted on the Australian Securities Exchange with an AUS$5.25million IPO. The listing gathered strong interest as the Singaporean firm is ahead of most small cap biotech and medtech companies on the ASX, many of whom are either still in clinical trials or attempting to have their products approved by regulatory bodies.